142 related articles for article (PubMed ID: 11762337)
1. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer.
Carnaghi C; Rimassa L; Garassino I; Santoro A
Ann Oncol; 2001; 12 Suppl 2():S119-23. PubMed ID: 11762337
[TBL] [Abstract][Full Text] [Related]
2. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung.
Harada M; Yokose T; Yoshida J; Nishiwaki Y; Nagai K
Lung Cancer; 2002 Nov; 38(2):177-84. PubMed ID: 12399130
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
[TBL] [Abstract][Full Text] [Related]
6. The value of immunohistochemical identification of neuroendocrine differentiation in non small cell lung carcinoma.
Słodkowska J
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():23-7. PubMed ID: 9337520
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
8. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
Kiriakogiani-Psaropoulou P; Malamou-Mitsi V; Martinopoulou U; Legaki S; Tamvakis N; Vrettou E; Fountzilas G; Skarlos D; Kosmidis P; Pavlidis N
Lung Cancer; 1994 Dec; 11(5-6):353-64. PubMed ID: 7535640
[TBL] [Abstract][Full Text] [Related]
9. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
11. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of neuroendocrine carcinoma of the breast.
Sapino A; Papotti M; Righi L; Cassoni P; Chiusa L; Bussolati G
Ann Oncol; 2001; 12 Suppl 2():S115-7. PubMed ID: 11762336
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of so-called neuroendocrine lung tumors.
Yesner R
Exp Mol Pathol; 2001 Jun; 70(3):179-82. PubMed ID: 11417996
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Howe MC; Chapman A; Kerr K; Dougal M; Anderson H; Hasleton PS
Histopathology; 2005 Feb; 46(2):195-201. PubMed ID: 15693892
[TBL] [Abstract][Full Text] [Related]
16. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
17. Reliability of commercially available immunocytochemical markers for identification of neuroendocrine differentiation in bronchoscopic biopsies of bronchial carcinoma.
Gosney JR; Gosney MA; Lye M; Butt SA
Thorax; 1995 Feb; 50(2):116-20. PubMed ID: 7701447
[TBL] [Abstract][Full Text] [Related]
18. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
19. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
[TBL] [Abstract][Full Text] [Related]
20. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
Vos MD; Scott FM; Iwai N; Treston AM
J Cell Biochem Suppl; 1996; 24():257-68. PubMed ID: 8806108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
